LRP1B and non-small cell lung carcinoma: In the non-small cell lung cancer cohort of Hellmann et al. (13), the patients harboring LRP1B mutation demonstrated an enhance objective response rate (ORR) and progression-free survival (PFS), the results were statistically significant (Figures 4E,F).